Kiora Pharmaceuticals, Inc.

Recent News

  • Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress

    Encinitas, California--(Newsfile Corp. - March 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the year ended December 31, 2022.CEO Commentary: "In 2022, we advanced our pipeline of three differentiated assets across rare, orphan and underserved eye disease indications," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "Enrollment is ongoing in our Phase 1b study of KIO-301 in patients with Retinitis Pigmentosa...

    2023-03-23 7:00 AM EDT
  • Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting

    Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, La., April 23-27, 2023. Further results from each of these three studies will be reported at the conference.A presentation will report interim results on safety, tolerability and efficacy from the ABACUS study, the ongoing, first-in-human clinical trial of...

    2023-03-10 7:00 AM EST
  • Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

    Encinitas, California--(Newsfile Corp. - February 7, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who...

    2023-02-07 7:00 AM EST
  • Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital

    Encinitas, California--(Newsfile Corp. - February 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has entered into a common stock purchase agreement for a committed equity financing (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC"), a long-standing investor in the Company. Under the Purchase Agreement and subject to certain terms and conditions including effectiveness of a related resale registration statement, the Company has the right, but not the obligation, to sell...

    2023-02-03 7:00 AM EST
  • Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website

    - Kiora is advancing a pipeline of therapeutics for rare and underserved ophthalmic diseases - - Anticipates reporting results in 1H 2023 from two clinical studies, one in patients with Retinitis Pigmentosa and another in patients with persistent corneal epithelial defects - - Expects to initiate Phase 2 trial in autoimmune disease patients experiencing ocular surface disease - Encinitas, California--(Newsfile Corp. - January 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that its president...

    2023-01-09 7:00 AM EST
  • Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023

    Encinitas, California--(Newsfile Corp. - January 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects ("PCED"), a rare ocular condition characterized by non-healing wounds on the surface of the eye. Results from the study are expected to be reported at an upcoming medical conference in the first half of 2023."This study is an important step to tackle some of...

    2023-01-03 7:01 AM EST
  • Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants

    Salt Lake City, Utah--(Newsfile Corp. - November 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today it has entered into warrant inducement offer letters to raise $3.12 million in gross proceeds from the exercise of 654,609 Class A warrants issued in the Company's public offering from July 2022. On November 17, 2022, the Company reduced the exercise price of all Class A warrants from $8.00 per share to $4.77 per share. On such date,...

    2022-11-18 8:30 AM EST
  • Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa

    Salt Lake City, Utah--(Newsfile Corp. - November 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with Retinitis Pigmentosa (RP). RP is a rare, inherited genetic eye disease resulting in degeneration of the retinal photoreceptors (rods and cones) and often significant loss of functional vision."We are thrilled the first patient has been treated and...

    2022-11-17 6:45 AM EST
  • Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End

    Salt Lake City, Utah--(Newsfile Corp. - November 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the three and nine months ended September 30, 2022.Management Discussion: "We're advancing a diverse development pipeline of three differentiated assets across rare and narrowly-defined patient populations requiring new treatment options for ophthalmic disease," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "Following our recent capital...

    2022-11-09 6:45 AM EST
  • Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease

    Salt Lake City, Utah--(Newsfile Corp. - October 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from a Phase 1 study of KIO-100 (formerly PP-001) demonstrate its potential as a treatment for non-infectious uveitis, an ophthalmic inflammatory disease. The results were published today in a paper titled "A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - a phase I clinical trial," in the journal Frontiers in...

    2022-10-17 8:00 AM EDT

Next »